PMID- 29325245
OWN - NLM
STAT- MEDLINE
DCOM- 20180202
LR  - 20181202
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 47
IP  - 1
DP  - 2018 Jan 8
TI  - [Clinical characteristics of high-grade B-cell lymphomas with rearrangement of 
      MYC, bcl-6 and bcl-2].
PG  - 14-18
LID - 10.3760/cma.j.issn.0529-5807.2018.01.004 [doi]
AB  - Objective: To investigate the clinicopathologic features of patients with 
      high-grade B-cell lymphomas (HGBL) that have rearrangements of MYC, bcl-6 and 
      bcl-2. Methods: One hundred and fifty-eight B-cell lymphomas patients from 
      Institute of Hematology and Blood Diseases Hospital from January 2016 to April 
      2017 were detected by fluorescence in situ hybridization (FISH) with double color 
      split-apart probes. Results: Among 158 B-cell lymphomas, 3 cases with MYC, bcl-2 
      and bcl-6 rearrangements were identified, 1 of which also had CCND1/IgH 
      translocation. All three patients were of older age, with poor prognostic 
      parameters, multiple organs involvements, elevated LDH and advanced-tumor stage. 
      Two of the three patients were treated with high-intensity chemotherapy and had 
      no remission with an overall survival of 9 months and 11 months respectively. One 
      patient had follow-up with no treatment. Histologically, all three cases showed a 
      spectrum of morphologic features. Although initially categorized as lymphoblastic 
      lymphoma, diffuse large lymphoma and mantle cell lymphoma respectively, two cases 
      were associated with germinal center B-cell (GCB) immunophenotype and 1 case with 
      non-GCB immunophenotype. They had a high proliferation index as assessed by 
      immunostaining for Ki-67 (60%-90%). Conclusions: MYC(+) bcl-2(+) bcl-6(+) HGBL is 
      an aggressive disease with multiple organ involvement, high serum LDH levels, 
      advanced stage disease, poor prognosis and shorter patient survival. The 
      diagnosis should be made by histopathology combined with FISH analysis. Its 
      separation from other types of B cell large cell lymphoma is of clinical 
      importance.
FAU - Gong, J Y
AU  - Gong JY
AD  - Department of Pathology, Institute of Hematology and Blood Diseases Hospital, 
      Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 
      300020, China.
FAU - Zhang, Y Z
AU  - Zhang YZ
FAU - Zhang, J D
AU  - Zhang JD
FAU - Zhang, W
AU  - Zhang W
FAU - Li, J Q
AU  - Li JQ
FAU - Ru, K
AU  - Ru K
FAU - Liu, E B
AU  - Liu EB
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (CCND1 protein, human)
RN  - 0 (DNA Probes)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 136601-57-5 (Cyclin D1)
SB  - IM
MH  - B-Lymphocytes
MH  - Cyclin D1/genetics
MH  - DNA Probes
MH  - *Gene Rearrangement
MH  - *Genes, myc
MH  - Germinal Center
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Large B-Cell, Diffuse/drug therapy/*genetics/pathology
MH  - Neoplasm Grading
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics
MH  - Proto-Oncogene Proteins c-bcl-6/*genetics
MH  - Translocation, Genetic
OTO - NOTNLM
OT  - Gene rearrangement, B-lymphocyte
OT  - In situ hybridization, fluorescence
OT  - Lymphoma, B-cell
OT  - Prognosis
EDAT- 2018/01/13 06:00
MHDA- 2018/02/03 06:00
CRDT- 2018/01/12 06:00
PHST- 2018/01/12 06:00 [entrez]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/02/03 06:00 [medline]
AID - 10.3760/cma.j.issn.0529-5807.2018.01.004 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2018 Jan 8;47(1):14-18. doi: 
      10.3760/cma.j.issn.0529-5807.2018.01.004.